Multiqure S.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2018-01-10
Share capital
22,574,931.90 PLN
Activity description

MultiQure is a life sciences company developing therapies for rare genetic neurodegenerative disorders. Its work includes the RNAi gene therapy MQ-201, which targets Huntington’s disease, and the company is preparing for clinical development. Its therapeutic portfolio also includes immuno-oncology.

Registered address
ul. Szczytnicka 11, 50-382 Wrocław, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-43264-33950-CUGUE-31

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 29 days early. All were audited by a statutory auditor.

  • 202513/07/2026
  • 202414/07/2025
  • 202304/07/2024
  • 202231/05/2023
  • 202130/06/2022
  • 202006/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 1.36
-0.02 (-1.73%)
1.361.371.381.391.401.3610:0012:0014:0016:00
Open
PLN 1.40
High
PLN 1.40
Low
PLN 1.36
Volume
256.73K
Avg. vol.
247.94K
Market cap
PLN 307.02M
P/E ratio
–
EPS
-PLN 12.58
Shares outstanding
225.75M
52-week
PLN 1.36 – 1.50
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 1.55mUSD -217.99kUSD -39.98m
Q1 2026USD 7.83kUSD -458.13kUSD -606.16k
Q4 2025USD 5.78kUSD -334.76kUSD -639.88k
Q3 2025USD 66.05kUSD -227.02kUSD -305.12k

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 29%
City · Wrocław6,194 / 13,650
Top 45%
Voivodeship · Dolnośląskie11,707 / 23,831
Top 49%
Country · Poland149,173 / 297,069
Top 50%

Results vs industry

Revenue
This companyUSD 284.78kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -2.47mMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 1.59mMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 1.24mMedianUSD 134.71kAverageUSD 3.04m

Offer

  • RNAi therapies
  • Huntington’s disease therapy
  • Immuno-oncology therapies

Websites

The site is available in: Polish and English.

  • multiqure.comHome page – multiQure
    WordPress 3.7Google AnalyticsGoogle Tag ManagerMeta PixelYoast SEONginx

Authorized Representatives

Filip Jan Jeleń age 49 – President of the Management Board
Sławomir Paweł Wójcik age 38 – Management Board Member

Manner of representation

The company is represented as follows: a) in the case of a one-person management board, the President of the Management Board is authorised to make declarations of will on behalf of the company independently; b) in the case of a multi-member management board, two members of the management board acting jointly, or one member of the management board acting jointly with a commercial proxy, are authorised to make declarations of will on behalf of the company.

Supervisory board

Paweł Bohdan Lewicki age 73 – Supervisory Board Member
Krzysztof Borys Siemionow age 49 – Supervisory Board Member
Mirosław Ciućman age 58 – Supervisory Board Member
Michał Dariusz Wnorowski age 53 – Supervisory Board Member
Michał Jerzy Żółtowski age 40 – Supervisory Board Member

Beneficial owners

Multiqure is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.

Subsidiaries

NameStake
BIO Animali sp. z o.o.
15%

Bank accounts

Was a VAT taxpayer from 2010-08-01 to 2026-08-20.

Reason for removal: Art. 96 ust. 9a pkt 2 (VAT returns not filed for 3 consecutive months or a quarter)

Debt

1 closed proceeding recorded in KRZ history.

Registration dateProceeding typeStatus
Jun 30, 2025
Petition to declare entrepreneur bankruptcy
Closed

MSiG notices

Publication dateEvent
Oct 30, 2025Commercial Companies Code notice
Jul 17, 2025Liquidation opened
Jul 9, 2025Call to creditors
Jul 9, 2025Call to creditors
Jul 9, 2025Call to creditors

Public aid

26 public aid cases recorded, with a total value of $29,993,841.

PurposeGross amount
Aid for research and development projects: experimental development
–
Aid for research and development projects: industrial research
–
Aid for research and development projects: industrial research
–

European Funds

10 projects co-financed from European Funds recorded, with total EU co-financing of $29,606,776.

ProjectEU co-financing
Development of a bispecific antibody fragment for simultaneous tumor control and recruitment of immune system cells (BIKE)
$7.3M
Development of a bispecific antibody fragment for simultaneous cancer treatment and recruitment of immune system cells [PHASE II]
$761.5K
Development of a first-in-class therapeutic medical device for use in the treatment of myasthenic crisis in patients with myasthenia gravis
$2.8M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Biotechna S.A.
Precisionlife Poland sp. z o.o.
Bioceltix S.A.
Famicordtx S.A.
VET Cell Tech sp. z o.o.
Vaxican sp. z o.o.
Vasa Therapeutics sp. z o.o.
Explorna Therapeutics sp. z o.o.
Nanoexpo sp. z o.o.
Personather sp. z o.o.

Change history

DateEvent
2026-08-04Share capital increase
2026-08-04Name change
2025-10-15Share capital increase
2025-03-24Share capital increase
2025-01-10Share capital increase

FAQ

Last updated: 2026-08-27